Bacterial Infections and Mycoses, Hematopoietic Stem Cell Transplantation
Conditions
Keywords
immunocompromized, hLF1-11, antimicrobial, peptide, lactoferrin
Brief summary
The safety and tolerability of hLF 1-11 has to be established first in HSCT recipients who are at risk of developing, but have not yet developed, infectious complications due to invasive fungal disease. These patients are different from healthy volunteers because they have received myeloablative treatment which not only arrests haematopoiesis resulting in neutropenia but also induces mucosal barrier injury both of which predispose to infections which typically occur during the week after transplant. It is therefore essential to know that hLF 1-11 is when given during neutropenia and mucosal barrier injury before infections ensue
Detailed description
Background: Human lactoferrin (hLF) is a glycoprotein containing 692 amino acids and found in the saliva, milk, tears, and other body fluids. Peptide representing the first cationic domain, i.e. a peptide comprising the first eleven residues of hLF (further referred to as hLF1-11) was significantly more effective than the full length hLF or the peptide representing the second cationic domain in killing a variety of bacteria in vivo. The mechanism of action comprises a number of independent factors. The classical way to explain the efficacy is the direct killing effect, which typically is observed in vitro at relatively high concentrations. The results of in vitro and in vivo experiments suggest that the mechanism of action is predominantly through the intermediary of cells and/or components of the host as opposed to a direct interaction with the pathogen. The objective is to develop hLF1-11 as an effective and safe antibacterial and antifungal for the treatment of fungal and bacterial infections that develop during the neutropenia that results from myeloablative therapy to prepare for a haematopoietic stem cell transplant (HSCT) formerly referred to as bone marrow transplant. Rates of infection and related morbidity are high in this population making it an attractive target for testing clinically the proof-of-principle that hLF1-11 can provided effective treatment. Subsequently, hLF1-11 will be developed further as a systemic antifungal agent.
Interventions
Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
Sponsors
AM-Pharma
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* admitted for an autologous HSCT after myeloablative therapy with high-dose melfalan * managed with a 4-lumen central venous catheter * BMI \<30 * able and willing to participate * has provided written informed consent * there is no medical reason for exclusion * has adequate renal function (creatinine \<110 µmol/L (man); \<90 µmol/L (woman)) * has adequate liver function (ASAT \<40 U; ALAT \<45 U; bilirubin \<10µmol/L) * has no known allergy to lactoferrin * has no history of hepatitis and is not HIV seropositive * if a woman, functionally post-menopausal
Exclusion criteria
* A history of, or presence of, significant respiratory, cardiovascular, neurological, haematological, endocrine, gastrointestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs (as judged clinically relevant by the investigator). * Participation in a study with a new chemical entity or new molecular entity 3 months before or participation in a study with a registered drug less than 5 times of the half life of the registered drug before entering the study. * A clinically relevant history of intolerance or hypersensitivity to the study drug, or its additives and excipients in the intravenous formulation. * Evidence of having serum hepatitis or carrying the hepatitis B surface antigen or Hepatitis C antibodies or being HIV positive. * Subjects, who in the opinion of the investigator should not, for reasons of safety, participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability by recording the vital signs, clinical chemistry, local tolerability and adverse events during the study | 28 Days |
Secondary
| Measure | Time frame |
|---|---|
| formation of antibodies anti-hLF 1-11 during the study. | 28 Days |
Countries
Netherlands
Outcome results
None listed